Teva Pharmaceutical Industries Limited

TEVA

US8816242098

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2024-04-18 pm EDT			5-day change	1st Jan Change
12.78 ^USD	-3.03%		-7.86%	+22.41%

Apr. 17	Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	CI
Apr. 16	Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	MT

Pharmapath Sarl acquired Greek Manufacturing Site of Teva Pharmaceutical Industries Limited.

March 21, 2022

Pharmapath Sarl acquired Greek Manufacturing Site of Teva Pharmaceutical Industries Limited (NYSE:TEVA) on March 22, 2022. KLC Law Firm acted as a legal advisor to Teva Pharmaceutical.

Pharmapath Sarl completed the acquisition of Greek Manufacturing Site of Teva Pharmaceutical Industries Limited (NYSE:TEVA) on March 22, 2022

Latest news about Teva Pharmaceutical Industries Limited

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)	Apr. 17	CI
Alvotech, Teva Win US FDA Approval for Selarsdi Injection to Treat Severe Plaque Psoriasis, Psoriatic Arthritis	Apr. 16	MT
Alvotech, Teva Get FDA Approval for Stelara Biosimilar Psoriasis Treatment	Apr. 16	DJ
Teva Pharmaceutical Unit Says Late-Stage Trial in China of Ajovy to Prevent Migraine Achieves Primary, Secondary Endpoints	Apr. 11	MT
Teva Confirms Efficacy and Safety of AJOVY for the Prevention of Migraine with Results from Phase 3 Trial in China	Apr. 11	CI
Teva Pharmaceuticals International, mAbxience Sign Licensing Deal for Oncology Biosimilar Candidate	Apr. 04	MT
UroGen Pharma Sues Teva Pharmaceuticals Over Alleged Patent Infringement of Jelmyto	Apr. 03	MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
US Appellate Court Vacates Ruling Maintaining Johnson & Johnson's Schizophrenia Drug Patent; Sends Back for Review	Apr. 01	MT
Teva Pharmaceutical to Get $150 Million From Carlyle Group's Abingworth for Asthma Therapy With Launch Therapeutics	Apr. 01	MT
JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11	Mar. 08	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $657,240, According to a Recent SEC Filing	Mar. 07	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,048,119, According to a Recent SEC Filing	Mar. 07	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,352,090, According to a Recent SEC Filing	Mar. 07	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $414,270, According to a Recent SEC Filing	Mar. 05	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $1,277,207, According to a Recent SEC Filing	Mar. 05	MT
Teva Pharmaceutical Industries Insider Sold Shares Worth $270,176, According to a Recent SEC Filing	Mar. 01	MT
Global markets live: Domino's Pizza, Walt Disney, Broadcom, Ryanair, Exxon Mobil, Goldman Sachs...	Feb. 26
Alvotech, Teva Say Simlandi Receives US FDA Approval as Interchangeable Humira Biosimilar	Feb. 26	MT
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Monday Ahead of Data-Packed Week	Feb. 26	MT
Teva Pharmaceutical's TEV-'574 Antibody Found to Be Safe in Studies	Feb. 20	MT
Teva Pharm to stay as unified drugmaker, sees big interest in API business, says CEO	Feb. 20	RE
Teva Pharmaceutical Shares Rise After Piper Sandler Upgrade	Feb. 12	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12	Feb. 12	MT
High-dose opioid reversal spray no better than lower dose in field, US study finds	Feb. 08	RE

Chart Teva Pharmaceutical Industries Limited

Duration

Period

Chart Teva Pharmaceutical Industries Limited

More charts

Company Profile

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT

More Strategies

Ratings for Teva Pharmaceutical Industries Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.78 USD

Average target price

15.74 USD

Spread / Average Target

+23.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED	+22.41%	14.93B
ELI LILLY AND COMPANY	+27.97%	676B
NOVO NORDISK A/S	+23.58%	554B
JOHNSON & JOHNSON	-7.02%	349B
MERCK & CO., INC.	+14.85%	318B
ABBVIE INC.	+6.25%	291B
ASTRAZENECA PLC	+2.96%	210B
NOVARTIS AG	-0.41%	204B
ROCHE HOLDING AG	-10.02%	194B
PFIZER, INC.	-11.81%	144B

Other Pharmaceuticals

Teva Pharmaceutical Industries Limited

Equities

TEVA

US8816242098

Pharmaceuticals

Pharmapath Sarl acquired Greek Manufacturing Site of Teva Pharmaceutical Industries Limited.

EPS Revisions